Clarity Pharmaceuticals (ASX:CU6) Research & Development: A$88.82 Mil (TTM As of Dec. 2025)


ASX:CU6 Clarity Pharmaceuticals Ltd ASX:CU6
39 GF Score
Price A$2.04
! 2 Warning Signs
View Full Analysis

What is Clarity Pharmaceuticals Research & Development?

Clarity Pharmaceuticals ASX:CU6 -3.32% 39 Research & Development is A$88.82 Mil as of Dec. 2025. GuruFocus rates ASX:CU6 with a GF Score™ of 39/100. The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Clarity Pharmaceuticals's Research & Development for the six months ended in Dec. 2025 was A$50.50 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was A$88.82 Mil.

Clarity Pharmaceuticals  (ASX:CU6) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Clarity Pharmaceuticals Research & Development Related Terms

Clarity Pharmaceuticals Research & Development Historical Data

* Premium members only.

The historical data trend for Clarity Pharmaceuticals's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Clarity Pharmaceuticals Research & Development Chart

Clarity Pharmaceuticals Annual Data
Trend Jun22 Jun23 Jun24 Jun25
Research & Development
18.90 31.46 45.78 66.88

Clarity Pharmaceuticals Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.71 26.08 28.56 38.32 50.50
ASX:CU6
39GF Score
Clarity Pharmaceuticals Ltd ASX:CU6
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Clarity Pharmaceuticals Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$88.82 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of A$88.82 Mil mean?
Clarity Pharmaceuticals (ASX:CU6) has a Research & Development of A$88.82 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Clarity Pharmaceuticals and its competitors.
Is Clarity Pharmaceuticals' Research & Development too high?
Clarity Pharmaceuticals' current Research & Development is A$88.82 Mil. Overall, Clarity Pharmaceuticals has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Clarity Pharmaceuticals' Research & Development compare to VRTX and REGN?
Clarity Pharmaceuticals' Research & Development of A$88.82 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Clarity Pharmaceuticals and its competitors. Clarity Pharmaceuticals's current Research & Development is A$88.82 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clarity Pharmaceuticals stock overvalued right now?
Clarity Pharmaceuticals (ASX:CU6) has a current Research & Development of A$88.82 Mil. The current Research & Development is A$88.82 Mil. Clarity Pharmaceuticals' overall GF Score™ is 39/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Clarity Pharmaceuticals (ASX:CU6), the current Research & Development is A$88.82 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Clarity Pharmaceuticals Business Description

Other Exchanges CLRPF:USA1F4:Germany
Address 2-4 Cornwallis Street, Suite 212a, National Innovation Centre, Eveleigh, Sydney, NSW, AUS, 2015
Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, using its SAR Technology platform. Clarity's Targeted Copper Theranostic (TCT) platform of products utilize pairing of copper isotopes, specifically copper-64 (Cu-64 or 64Cu) for imaging and copper-67 Cu-67 or 67Cu) for therapy, which delivers accuracy and precision in the treatment of a range of cancers. The company's clinical development pipeline includes SAR-bisPSMA, SAR-Bombesin, and Sartate, in their different stages of development for the diagnosis and/or treatment of various cancers. Clarity operates in a single segment, which is the development of radiopharmaceuticals. Geographically, it operates in Australia and the United States.
39GF Score

Get the complete analysis for ASX:CU6

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$2.04
Price